Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer

详细信息    查看全文

• 作者：Wen-Ji Zhang^a ; Yong Li^b ; Meng-Ning Wei^a ; Yao Chen^a ; Jian-Ge Qiu^a ; Qi-Wei Jiang^a ; Yang Yang^a ; Di-Wei Zheng^a ; Wu-Ming Qin^a ; Jia-Rong Huang^a ; Kun Wang^a ; Wen-Juan Zhang^c ; Yi-Jun Wang^d ; Dong-Hua Yang^d ; Zhe-Sheng Chen^d ; ^e ; ^{chenz@stjohns.edu} ; Zhi Shi^a ; ^{tshizhi@jnu.edu.cn}
• 关键词：Regorafenib ; Lapatinib ; Targeted therapy ; Combination chemotherapy ; Colorectal cancer
• 刊名：Cancer Letters
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：386
• 期：Complete
• 页码：100-109
• 全文大小：2762 K
• 卷排序：386

文摘

Regorafenib and lapatinib have synergistic anticancer effects on human CRC in vitro and in vivo. Regorafenib and lapatinib do not influence on each plasma concentration. The synergistic activity warrants further clinical investigation of the combination as a potential treatment for CRC patients.